Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Clin Pathol. 2013 Oct;140(4):544-9. doi: 10.1309/AJCPM2Z4NGIIPBGE.

CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.

Author information

1
Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan; e-mail: mtagawa@chiba-cc.jp.

Abstract

OBJECTIVES:

To pathologically distinguish mesothelioma from lung carcinoma, particularly adenocarcinoma.

METHODS:

We conducted immunohistochemical analyses on clinical specimens, including 26 cases of mesothelioma, 28 cases of lung adenocarcinoma, and 33 cases of lung squamous cell carcinoma.

RESULTS:

We found that CD90 expression was useful in making a differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma, whereas sarcomatoid mesothelioma and lung carcinoma specimens, irrespective of the histologic types, were negative in general. The sensitivity and specificity of CD90 expression in epithelioid mesothelioma and lung adenocarcinoma were comparable to those of well-established markers used for the differential diagnosis.

CONCLUSIONS:

These data collectively indicate that CD90 is a novel diagnostic marker that contributes to a diagnosis of epithelioid mesothelioma.

KEYWORDS:

CD90; Immunohistochemistry; Lung carcinoma; Mesothelioma

PMID:
24045552
DOI:
10.1309/AJCPM2Z4NGIIPBGE
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center